Anti-Inflammatory Strategies for Ventricular Remodeling Following ST-Segment Elevation Acute Myocardial Infarction  by Seropian, Ignacio M. et al.
Journal of the American College of Cardiology Vol. 63, No. 16, 2014
 2014 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2014.01.014STATE-OF-THE-ART PAPERS
Anti-Inflammatory Strategies for
Ventricular Remodeling Following
ST-Segment Elevation Acute
Myocardial Infarction
Ignacio M. Seropian, MD,* Stefano Toldo, PHD,yz Benjamin W. Van Tassell, PHARMD,yzx
Antonio Abbate, MD, PHDyz
Buenos Aires, Argentina; and Richmond, VirginiaAFrom the *Cardio
yVCU Pauley He
ginia; zVictoria Jo
Richmond, Virgin
University, Richm
by research grants
of Health. Dr. A
XOMA; has lectur
for Gilead, Jansse
Dr. Van Tassell h
consulted for No
relevant to the con
Manuscript rece
28, 2013, acceptedcute myocardial infarction (AMI) leads to molecular, structural, geometric, and functional changes in the heart in a
process known as ventricular remodeling. An intense organized inﬂammatory response is triggered after myocardial
ischemia and necrosis and involves all components of the innate immunity, affecting both cardiomyocytes and
noncardiomyocyte cells. Inﬂammation is triggered by tissue injury; it mediates wound healing and scar formation
and affects ventricular remodeling. Many therapeutic attempts aimed at reducing inﬂammation in AMI during the
past 3 decades presented issues of impaired healing or increased risk of cardiac rupture or failed to show any
additional beneﬁt in addition to standard therapies. More recent strategies aimed at selectively blocking one of
the key factors upstream rather than globally suppressing the response downstream have shown some promising
results in pilot trials. We herein review the pathophysiological mechanisms of inﬂammation and ventricular
remodeling after AMI and the results of clinical trials with anti-inﬂammatory strategies. (J Am Coll Cardiol
2014;63:1593–603) ª 2014 by the American College of Cardiology FoundationAcute myocardial infarction (AMI) remains a leading cause
of death worldwide (1). Despite reperfusion strategies, pa-
tients with large AMI who survive the initial ischemic event
are at higher risk of the development of HF in a process
referred as ventricular remodeling (2). The term ventricular
remodeling, ﬁrst used by Pfeffer et al. (3) in 1985, refers to
changes in ventricular geometry (dilation, sphericity, wall
thinning) and stiffness, as well as epigenetic, molecular, and
functional changes that include both cardiomyocytes and
other cells of the heart, in the infarct area, and in the remote
viable myocardium (4). Ventricular remodeling is a powerful
prognostic factor after AMI (5) and has been identiﬁed as a
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January 8, 2014.Despite modern reperfusion strategies (with a goal of door-
to-balloon time of <90 min) and neurohormonal blockade
therapies (inhibitors of the renin-angiotensin-aldosterone
system and of the adrenergic system), the incidence of HF
after ST-segment elevation AMI remains unacceptably high,
and there is an urgent need for novel treatments to improve
post-AMI quality of life and survival. This suggests that the
current therapeutic paradigm still misses one or more key
pathophysiological mechanisms.
Parallel to the interest in reperfusion and neurohormonal
blockade, much interest has been devoted to understanding
the role of inﬂammation in AMI (6), leading to a large
volume of experimental preclinical data and clinical obser-
vation evidence but, unfortunately, not to any clinically
effective anti-inﬂammatory treatments for AMI.
The aim of this review is to discuss the activation of the in-
ﬂammatory response and its role in post-AMI ventricular
remodeling, the basis of preclinical research, the potential rea-
sons for failure to translate, and future perspectives in the ﬁeld.Pathophysiology
The heart has limited anaerobic metabolism and depends
on oxygen. During AMI, the oxygen supply is reduced
and adenosine triphosphate is no longer produced, with
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1594impairment of the sodium-
potassium (Naþ-Kþ ATPase)
pump and loss in membrane in-
tegrity, leading to death (6,7).
After the initial ischemic
event, an intense inﬂammatory
response is observed, mainly
characterized by inﬁltration with
neutrophils, followed by mono-
cytes/macrophages and lym-
phocytes. Inﬁltrating monocytes
ﬁrst express a proinﬂammatory
(M1) phenotype, followed by a
switch to an angiogenic and ﬁb-
rotic phenotype (M2) (8,9). In-
ﬁltrating lymphocytes, although
smaller in number, also play a
key role in remodeling. CD4
T-helper lymphocytes shift to a
Th1 phenotype, whereas regula-
tory T cells are necessary for res-
olution of inﬂammation (6,10). In
the initial few days, the infarct
starts to expand as a result of the
loss of passive tension. Infarct
expansion is characterized by
acute ventricular dilation, infarct
wall thinning (without additional
necrosis), and cardiomyocyte
stretching. Extracellular matrixdegradation promotes cardiomyocyte slippage and scar thin-
ning. Cardiac ﬁbroblasts generate a noncompliant collagen
scar to maintain the ventricular geometry and prevent
aneurysm formation. This process is followed by maturation
of the scar. Apoptosis of inﬁltrating neutrophils and a
phenotypic switch in macrophages and lymphocytes are
involved in the resolution of the inﬂammatory process
(6,8,10).
This healing process in post-AMI ventricular remodeling
can be divided into 3 partially overlapping phases (6): 1. the
inﬂammatory phase; 2. the proliferative phase; and 3. the
maturation phase. The inﬂammatory phase is mediated by
cytokines leading to recruitment of leukocytes. Cell debris
activates the inﬂammasome, a macromolecular structure that
activates caspase-1 and the conversion of pro-interleukin
(IL)-1b to mature IL-1b (11,12). The formation and acti-
vation of the inﬂammasome amplify tissue injury and the
local and systemic inﬂammatory response (11,12). Leuko-
cytes remove necrotic cells while releasing cytokines and
growth factors. Neutrophils eventually undergo apoptosis,
leading to a gradual disappearance of the inﬁltrate. In the
proliferative phase, ﬁbroblasts proliferate and synthesize
collagen to form a scar.
The most effective therapeutic intervention to reduce
myocardial injury is timely and effective myocardial reper-
fusion. The process of myocardial reperfusion, however, canitself induce further cardiomyocyte death with a phenome-
non known as myocardial reperfusion injury (13).
Over time, the increased wall stress and neurohormonal
activation, however, causes apoptosis of the cardiomyocytes
in the nonischemic area leading to left ventricular wall
thinning and chamber dilation, producing a spherical ge-
ometry with an increased left ventricular mass but decreased
relative wall thickness (eccentric hypertrophy) (7). Al-
though ventricular dilation observed during the initial
phases may be beneﬁcial in maintaining cardiac output via
an increase in ventricular ﬁlling volume, these compensa-
tory mechanisms become detrimental when sustained over
time, leading to cardiac dysfunction and heart failure
(Fig. 1).
Anti-Inﬂammatory Treatments
Several experimental studies in animals have explored
treatments aimed at modulating inﬂammation during AMI.
Only those strategies that were eventually tested in clinical
studies are discussed in detail in this review.
Glucocorticoids. Glucocorticoids are potent anti-inﬂammatory
agents that act via 3 mechanisms (14): ﬁrst, binding a receptor in
the cytosol that moves to the nucleus and binds as a dimer
to DNA sequences called glucocorticoid-responsive ele-
ments, modifying DNA transcription; second, the cortisol-
glucocorticoid receptor complex inhibits nuclear factor kB,
regulating the transcription of proinﬂammatory mediators; and
third, via membrane-associated receptors (nongenomic path-
ways) independent of gene expression, such as activation of
endothelial nitric oxide synthase.
In experimental animal models, treatment with glucocor-
ticoids showed conﬂicting results (15,16), associated with
impaired healing, scar thinning, ventricular aneurysm, and
increased risk of ventricular rupture (17,18). Several rather
small clinical studies tested the effects of glucocorticoids in
patients with AMI, showing conﬂicting results. A recent
systematic review and meta-analysis (16 studies, n ¼ 4,000)
in AMI included registries, case-control studies, and non-
randomized and randomized clinical trials (RCTs) (19).
The analysis of mortality (11 studies, n ¼ 2,646) showed a
26% relative risk reduction with glucocorticoid therapy and
no excess risk of rupture. However, there was no signiﬁcant
survival beneﬁt when only RCTs or larger studies (n ¼ >100)
were included. Differences in study design, investigational
agents (e.g., hydrocortisone, dexamethasone, prednisone,
methylprednisone), and dosing regimens make it difﬁcult to
draw any deﬁnitive conclusions. Finally, none of the studies
used a percutaneous coronary intervention (PCI) as a reper-
fusion strategy, and some studies were performed with no
reperfusion strategy used. Overall, treatment with glucocor-
ticoids was not harmful in this group and in some instances
might be even beneﬁcial. The impairment in infarct healing
with corticosteroids is not supported by clinical trials, and it
is either only seen in some subsets of patients (i.e., long-term
steroid use, ﬁrst AMI, transmural AMI without reperfusion)
Figure 1 Pathophysiology of Ventricular Remodeling After Acute Myocardial Infarction
After coronary artery occlusion, ischemia ensues, cardiomyocytes die, and healing and scar formation begin (top). The remodeling process can lead to left ventricular (LV)
dilation, initially with preservation of ejection fraction (EF) at ﬁrst (Frank-Starling mechanism), but infarct expansion with scar thinning may occur (left), or compensatory
hypertrophy of the noninfarcted area may be sufﬁcient to limit, at least initially, ventricular dilation (right). If the stimuli for adverse remodeling process persist over time,
ventricular dilation and wall thinning lead to reduced ejection fraction (EF) and heart failure (bottom). Inﬂammation plays a critical role in ventricular remodeling (center).
Leukocytes (macrophages [M], lymphocytes [L], monocytes [MC], neutrophils [N]) leave the bloodstream via endothelial cells (EC) and clear necrotic cardiomyocytes (CM),
whereas ﬁbroblasts (F) produce a collagen-based scar. LV ¼ left ventricular.
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considering the uncertain beneﬁt and the adverse effects of
volume retention, edema, hyperglycemia, and muscular at-
rophy, the use of glucocorticoid in AMI is currently not
advised. Accordingly, current clinical guidelines for ST-
segment elevation myocardial infarction (STEMI) recom-
mend against glucocorticoid treatment (20,21).
Nonsteroidal anti-inﬂammatory drugs. Nonsteroidal anti-
inﬂammatory drugs (NSAIDs) are also broad anti-
inﬂammatory drugs that inhibit prostanoid production from
arachidonic acid through inhibition of cyclooxygenase (COX)
(22). Two isoforms of COX exist: COX-1 is constitutivelyexpressed in most cell types and is the only COX isoform in
platelets, whereas COX-2 expression is mainly induced dur-
ing inﬂammation.
Experimental studies with NSAIDs showed conﬂict-
ing results (23–27); they seem to delay rather than
decrease ischemic necrosis (28), with the risk of allowing
ventricular wall tension to act on deformable myocar-
dium for a longer time leading to aneurysm formation and
rupture (29).
Observational clinical studies showed an association be-
tween NSAID use, worse clinical outcome (30), and ven-
tricular rupture after AMI (31). An experimental study in
Figure 2 Anti Inﬂammatory Targets in Cardiac Remodeling After Acute Myocardial Infarction
Mechanisms of action for the different anti-inﬂammatory treatments. (Upper left) Glucocorticoids bind a receptor (GR) in the cytosol that homodimerizes and translocates to the
nucleus to exert anti-inﬂammatory effects, whereas other nongenomic effects are related to endothelial nitric oxide synthase (e-NOS) stimulation and mitogen-activated protein
kinases (MAPKs). NF-kB ¼ nuclear factor kB. (Upper right) Nonsteroidal anti-inﬂammatory drugs (NSAIDs) inhibit cyclooxygenase enzyme (COX) either selectively (COX 1 or 2)
or non-selectively. (Left) Matrix metalloproteinases (MMPs) are endoproteinases that degrade the extracellular matrix participating in migration of inﬂammatory cells. TIMPs ¼
Tissue inhibitors of metalloproteinases. (Right) Integrins are leukocyte cell adhesion molecules, essential for inﬁltrating the myocardium through the endothelium. P-selectin is
also expressed in activated platelets. EC ¼ endothelial cell. (Bottom left) Tumor necrosis factor (TNF)-a is cytokine with pleiotrophic effects; whereas signaling through the
TNF-a receptor I (TNFRI) is proinﬂammatory, signaling through the TNFRII is beneﬁcial. Etarnecept is a recombinant soluble TNFR (sTNFR). Interleukin (IL)-1b is activated from
pro-IL-1b through caspase-1 (Casp-1), and alpha1-antitrypsin (AAT) inhibits Casp-1. IL-1 binds the IL-1 receptor (IL-1R) as well as the IL-1R antagonist (IL-1Ra). Anakinra is a
recombinant IL-1Ra, whereas IL-1Trap is a soluble IL-1R. Ab ¼ antibody. (Bottom right) The classic pathway of the complement cascade starts with C1 activation. A soluble
C1 receptor (sC1R) or direct C1 inhibitors inhibit this pathway. C5 is downstream activated, leading to inﬂammation and cardiomyocyte injury. C1INH ¼ C1 esterase inhibitor.
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that treatment with either ibuprofen or indomethacin led to
infarct expansion (32). Although the majority of these
studies are dated and involved patients with nonreperfused
AMI who are at greatest risk of infarct expansion, NSAIDs
also led to a signiﬁcant increase in blood pressure values,
reduced renal blood ﬂow, increased platelet aggregation,
and increased risk of gastrointestinal bleeding. Therefore,
current clinical guidelines recommend against NSAID
treatment, and discontinuation at the time of STEMI is
indicated (20,21). Moreover, long-term NSAID use isassociated with an increased risk of incident and recurrent
AMI (33,34).
Selective COX-2 inhibitors also showed conﬂicting
results in experimental studies in AMI (35–39). In the
NUT-2 (Nonsteroidal Anti-Inﬂammatory Drugs in Un-
stable Angina Treatment-2) pilot study (n ¼ 120) melox-
icam, a preferential COX-2 inhibitor, showed a decreased
composite endpoint of recurrent angina, AMI, and
death when treatment was given for 30 days (40). COX-2
inhibitors, however, have effects on blood pressure and
renal blood ﬂow similar to those of NSAIDs, and therefore
JACC Vol. 63, No. 16, 2014 Seropian et al.
April 29, 2014:1593–603 Inflammation and Ventricular Remodeling With STEMI
1597current guidelines advise against their use in patients with
AMI.
Integrins. Activated neutrophils play a key role in reper-
fusion injury (41). Neutrophils inﬁltrate the ischemic myo-
cardium through endothelial adhesion molecules, which lead
to the development of antibodies against these adhesion
molecules (CD18, CD11) with promising results in exper-
imental AMI in mice (42), rabbits (43), dogs (44–46), and
primates (47) (Fig. 2).
The LIMIT-AMI (Limitation of Myocardial Infarction
Following Thrombolysis in Acute Myocardial Infarction)
trial (48) in STEMI (394 patients with ﬁbrinolysis) showed
that treatment with a humanized monoclonal antibody
against CD18 (rhuMAb CD18) failed to improve coronary
reperfusion on angiography, ST-segment resolution, or
infarct size at 5 days, with a nonsigniﬁcant trend toward
increased infections and bleeding complications. The
HALT-AMI trial (49) also failed to show any beneﬁcial
effect in STEMI (420 patients with primary PCI) treated
with a recombinant antibody against CD11/CD18
(Hu23F2G). Although infections were also signiﬁcantly
increased with Hu23F2G, a trend toward a decreased inci-
dence of death, reinfarction, and HF at 30 days was observed.
A possible explanation for negative results observed with
these agents is that the duration of ischemia observed in trials
is longer than that in experimental models of ischemia-
reperfusion, leading to irreversible endothelial cell barrier
damage and thus limiting the efﬁcacy of the proposed
intervention.
P-selectin is another adhesion molecule expressed on
activated endothelial cells and platelets and is essential for
leukocyte tethering and rolling in the vessel wall to in-
ﬁltrate the myocardium, similar to CD18/11b (50). In
addition, P-selectin is highly expressed in activated but
not resting platelets. In experimental reperfused AMI, a
soluble P-selectin glycoprotein ligand-immunoglobulin was
shown to decrease infarct size and inﬂammation (51). A
phase II trial (SELECT-ACS [Effects of the P-SelectinTable 1 Clinical Studies With Pharmacological Strategies Against In
Study,
Year (Ref. #) Population (N)
Reperfusion
Strategy Treatment
Pri
LIMIT-AMI,
2001 (48)
STEMI <12 h
(394)
rtPA MAb for CD18
(rhuMAb CD18)
in 2 doses
CTFC
(9
HALT-AMI,
2002 (49)
STEMI <6 h
(420)
PCI Recombinant Ab
for CD11/CD18
(Hu23F2G) in
2 doses
Infar
at
SELECT-ACS,
2013 (52)
NSTEMI
(544)
PCI MAb for P-selectin
(inclacumab)
in 2 doses
Chan
(ba
16
Ab ¼ antibody; CTFC ¼ corrected Thrombolysis In Myocardial Infarction frame count; MAb ¼ monoclonal
intervention; RRR ¼ relative risk reduction; rtPA ¼ recombinant tissue plasminogen activator; rhuMAb ¼Antagonist Inclacumab on Myocardial Damage After
Percutaneous Coronary Intervention for Non-ST Eleva-
tion Myocardial Infarction] trial) in 322 patients with
non-STEMI showed that treatment with a monoclonal
antibody against P-selectin (inclacumab) appears to
reduce myocardial damage as measured by creatine
phosphokinase and troponin release (52). Nevertheless,
the clinical event rates trended in the opposite direction,
with a trend toward more unfavorable events in treated
versus untreated patients (53). Moreover, the effects of
these drugs on long-term ventricular remodeling were not
assessed, and no study has follow-up longer than 30 days,
making it difﬁcult to translate the results to clinical
practice. Clinical studies targeting integrins are summa-
rized in Table 1.
Complement cascade. Complement cascade is activated
early during AMI and actively participates in ischemia-
reperfusion injury via various mechanisms: activating leuko-
cytes and endothelial cells, increasing proinﬂammatory
cytokine release, and causing cardiomyocyte cell death (6,41).
Complement cascade is activated via a classic and alternative
pathway, whereas complement cell death is mediated by the
membrane attack complex (Fig. 2) (54).
Blockade of the classic pathway of complement activation
by a C1 esterase inhibitor was beneﬁcial in experimental
models of ischemia-reperfusion in cats (55), rats (56–58),
pigs (59), and rabbits (60). However, higher doses of C1
esterase inhibitor showed no protective effects and may even
promote coagulation and inhibit thrombolysis (61).
In a safety clinical study, treatment with a C1 inhibitor
was well tolerated, and no drug-related adverse effects were
observed in 22 patients with STEMI reperfused with
ﬁbrinolysis (62). Of note, the drug was given at least 1 to 2.5
h after termination of ﬁbrinolytics to avoid plasmin inhibi-
tion as a prothrombotic effect.
Complement depletion with cobra venom factor (CVF)
reduces infarct size in dogs after ischemia-reperfusion (63).
The immunogenicity of CVF led to the development oftegrins
mary Endpoint
(Follow-Up) Results Observations
on angiography
0 min)
CTFC: Placebo 46  13 vs.
51  32 and 45  29
rhuMAb CD18 (low and
high dose, respectively)
(p ¼ NS)
No difference in secondary
outcomes (infarct and
ST-segment resolution)
ct size (SPECT)
5 to 9 days
Placebo 16% vs. 17.2% and
16.6% Hu23F2G (low and
high dose, respectively)
(p ¼ 0.8)
No difference in clinical
events at 1 month
ge in troponin I
seline vs.
and 24 h)
16 h: placebo 77% vs. 38%
inclacumab high dose
(RRR: 22%, p ¼ 0.07)
24 h: placebo 58% vs. 19%
inclacumab high dose
(RRR: 24%, p ¼ 0.05)
No effect for the low
dose. Trend toward
more clinical events
with treatment
antibody; NSTEMI ¼ non–ST-segment elevation myocardial infarction; PCI ¼ percutaneous coronary
humanized monoclonal antibody; STEMI ¼ ST-segment elevation myocardial infarction.
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reperfusion injury in mice (64).
C5 is activated both in the classic and alternative pathways
and is a key member of the membrane attack complex. C5a
is the most potent anaphylatoxin that attracts and stimulates
neutrophils, causing their sequestration within capillaries
(54). Inhibition of C5 activation using monoclonal anti-
bodies was shown to reduce infarct size in rats with ischemia-
reperfusion through reduction in neutrophil inﬁltration and
cardiomyocyte apoptosis (65).
Pexelizumab is a humanized antibody against C5 that was
tested in different scenarios of AMI, unfortunately without
the expected beneﬁcial effect. The COMPLY (COMPle-
ment inhibition in myocardial infarction treated with
thromboLYtics) trial (66) (943 patients with ﬁbrinolysis)
failed to reduce infarct size or reduce major adverse cardiac
adverse events (MACE) in patients with STEMI. The
phase II COMMA (COMplement inhibition in Myocardial
infarction treated with Angioplasty) trial (67), tested the ef-
fects of pexelizumab in a similar group of patients (STEMI
within 6 h, 960 patients) but undergoing primary PCI.
Although no differences in infarct size measured with crea-
tine phosphokinase area under curve were observed, treat-
ment with pexelizumab showed a signiﬁcant decrease in
mortality at 90 days (1.8% vs. 5.9% for placebo, p ¼ 0.014).
Therefore, the APEX-AMI (Assessment of Pexelizumab in
Acute Myocardial Infarction) trial (68), a phase III RCT
(5,754 patients with primary PCI) was completed to conﬁrm
and expand the results of the COMMA trial. Unfortunately,
pexelizumab showed no effect on the primary endpoint of
mortality at 30 days or MACE at 3 months. Clinical studies
targeting the complement are summarized in Table 2.
Cytokines. Leukocytes are mobilized to the site of injury by
cytokines and chemokines. IL-1 is the prototypical proin-
ﬂammatory cytokine (69). Two forms of IL-1 exist, IL-1a
and IL-1b. Both forms are synthesized as precursors;
pro-IL-1a is, however, already active and has also a role as
nuclear transcription factor, whereas pro-IL-1b is inactive
until cleaved by caspase-1 in the inﬂammasome to becomeTable 2 Clinical Studies With Pharmacological Strategies Against th
Study,
Year (Ref. #)
Population
(N)
Reperfusion
Strategy Treatment
Primar
(Fo
De Zwaan,
2002 (62)
STEMI (22) STK or rtPA C1 inhibitor
(Cetor) in
3 doses
Safety (4
COMPLY,
2003 (66)
STEMI <6 h
(943)
STK, rtPA
and other
ﬁbrinolytics
MAb for C5
(pexelizumab)
bolus  infusion
Infarct s
CK-MB
COMMA,
2003 (67)
STEMI <6 h
(960)
PCI MAb for C5
(pexelizumab)
bolus  infusion
Infarct s
CK-MB
APEX-AMI,
2007 (68)
STEMI <6 h
(2,885)
PCI MAb for C5
(pexelizumab)
bolus þ infusion
All-cause
(30 da
AUC ¼ area under curve; CI ¼ conﬁdence interval; CK-MB ¼ creatine kinase-myocardial band; RR ¼ relactive IL-1b. Both IL-1a and IL-1b bind the same IL-1
receptor 1 (IL-1R1) membrane signaling receptor. IL-1b
is considered the predominant circulating form of IL-1. IL-1
binds a signaling membrane receptor (IL-1R1) associated
with an accessory protein (IL-1 accessory protein) that binds
the myeloid differentiation factor 88. This messenger acti-
vates IL-1 receptor–associated kinase type 4 releasing nuclear
factor kB, which transports to the nucleus to synthesize most
proinﬂammatory cytokines and amplify the inﬂammatory
response. A type 2 receptor transduces no signal. IL-1 re-
ceptor antagonist is a third member of IL-1 family that binds
to the IL-1R1 without eliciting any downstream signaling
(70). Experimental studies showed that the IL-1 family is up-
regulated in AMI (71,72), leading to ventricular dysfunction
(12,73–75) and inﬂammation (70). In pre-clinical models
of experimental AMI in mice, IL-1 blockade either with
the human recombinant IL-1 receptor agonist (anakinra)
(76), a soluble receptor acting as a trap for circulating IL-1b
and IL-1a (77), antibodies against IL-1b (78,79), down-
stream myeloid differentiation factor 88 (80) inhibition, or
genetic blockade (81), all improved ventricular remodeling
and cardiac function after AMI without impairing infarct
healing or scar formation (12) (Fig. 2).
The encouraging results of IL-1 blockade in pre-clinical
models, led to 2 pilot clinical trials with anakinra: the
VCU-ART (Virginia Commonwealth University Acute
Remodeling Trial) (82) and VCU-ART2 (83). These phase
II pilot studies enrolled 40 patients with reperfused STEMI
with primary PCI randomized to daily treatment with
anakinra or placebo for 14 days. Anakinra was well tolerated
and associated with a favorable effect on C-reactive protein
(CRP) levels and trends toward more favorable left ven-
tricular remodeling and a reduced incidence of HF at 3
months (30% vs. 5%). Of note, the incidence of HF was
30% at 3 months in this placebo cohort of patients despite
nearly normal ventricular dimensions and function, which
suggests that with current reperfusion and therapeutic stra-
tegies, HF after STEMI may occur also with slight or
undetectable ventricular remodeling. A third pilot studye Complement Cascade
y Endpoint
llow-Up) Results Observations
8 h) Cetor was well tolerated
and inhibited C4
fragments
Cetor reduces AUC for
CK-MB 57%, p ¼ 0.001
ize by
AUC (72 h)
CK-MB AUC (ng/ml): placebo
5,230 vs. 4,952 (bolus)
and 5,557 (with infusion)
Pexelizumab (p ¼ NS)
No difference in clinical
events at 3 months
ize by
AUC (72 h)
CK-MB AUC (ng/ml): placebo
4,393 vs. 4,526 (bolus)
and 4,713 (with infusion)
Pexelizumab (p ¼ NS)
Pexelizumab (bolus þ infusion)
reduced 90-day mortality
(RR: 0.3, 95% CI: 0.46–1.29,
p ¼ 0.014)
mortality
ys)
No difference: placebo
4.1% vs. pexelizumab
3.9%, p ¼ 0.78
No difference in other
clinical endpoints
ative risk; STK ¼ streptokinase; other abbreviations as in Table 1.
Table 3 Clinical Studies With Pharmacological Strategies Against Cytokines
Study,
Year (Ref. #)
Population
(N)
Reperfusion
Strategy Treatment
Primary Endpoint
(Follow-Up) Results Observations
VCU-ART,
2010 (82)
STEMI (10) PCI Anakinra (IL-1Ra)
for 14 days
Ventricular remodeling
as DLVESVI on
cardiac MRI
(3 months)
Placebo: þ2 ml/m2 vs.
anakinra: 3.2 ml/m2
(p ¼ 0.033)
DCRP correlated with
remodeling (r2 ¼ 0.71,
p ¼ 0.02); more
events in the placebo
group
VCU-ART2,
2013 (83)
STEMI (30) PCI Anakinra (IL-1Ra)
for 14 days
Ventricular remodeling
as DLVESVI on
cardiac MRI
(3 months)
Placebo: þ1.0 ml/m2 vs.
anakinra: þ1.4 ml/m2
(p ¼ 0.8)
VCU-ART and VCU-ART2
combined events showed
reduction in HF with
anakirna (30% vs. 5%,
p ¼ 0.035)
Padﬁeld GJ et al,
2013 (108)
NSTEMI at
day 3 (26)
NS Etarnecept
(TNF-a blocker)
Leukocytes, cytokines,
platelet activation,
endothelial dysfunction
and ﬁbrinolysis (24 h)
Reduced neutrophil
count and IL-6 but
increased platelet-
monocyte aggregation
No effect on endothelial
and ﬁbrinolytic functions
DCRP¼ change in C-reactive protein level; HF¼ heart failure; HR ¼ hazard ratio; IL¼ interleukin; IL-1Ra ¼ interleukin-1 receptor antagonist; LVEF ¼ left ventricular ejection fraction; DLVESVI ¼ change in left
ventricular end-systolic volume index; LVESVI ¼ left ventricle end-systolic volume index; MRI ¼ magnetic resonance imaging; NYHA ¼ New York Heart Association; TNF ¼ tumor necrosis factor; NS ¼ not
speciﬁed; other abbreviations as in Table 1.
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1599(VCU-ART3) is being planned that will test 2 different
doses of anakinra in patients with STEMI who are at
increased risk of HF (84).
Alpha1-antitrypsin (AAT) is an abundant serine protease
inhibitor, up-regulated in AMI as an acute phase reactant
(85). AAT also exerts anti-inﬂammatory effects indepen-
dent of the serine protease-inhibiting activity, including
inhibition of caspase-1 (86) (Fig. 2). Experimental studies
showed that AAT improved ventricular remodeling after
reperfused AMI in mice (86). A phase II pilot trial will test
the safety and efﬁcacy of AAT in patients with STEMI (87).
IL-6 is a key secondary cytokine produced by inﬂammatory
cells in response to various stimuli including IL-1 (88,89).
IL-6 ﬁrst binds to the IL-6 receptor (CD126), and the sub-
sequent complex associates with the receptor subunit glyco-
protein 130 (CD130) (89). Experimental studies provided
conﬂicting and inconclusive results regarding the role IL-6 in
ventricular remodeling (90,91). Tocilizumab is a humanized
monoclonal antibody against the IL-6 receptor (92), currently
being tested in an RCT in patients with non-STEMI (93).
IL-10, in contrast, is an anti-inﬂammatory cytokine.
Experimental studies showed conﬂicting results with some
showing protective and some showing detrimental effects of
IL-10 (94,95). To date, no clinical study in patients with
AMI has been performed.
CRP is synthesized and released from hepatocytes in
response to cytokines, primarily IL-6. Experimental studiesTable 4 Clinical Studies With Pharmacological Strategies Against M
Study,
Year (Ref. #) Population (N)
Reperfusion
Strategy Treatmen
PREMIER,
2006 (113)
STEMI þ LVEF
15%–40% (203)
Any or none
(90% PCI)
PG-116800
(MMP inhibi
from day 2
TIPTOP,
2013 (115)
STEMI <12 h þ
LVEF <40% (120)
PCI Doxycycline
(100 mg tw
daily) for 14
MMP ¼ metalloproteinase; other abbreviations as in Tables 1 and 3.have shown that CRP can promote inﬂammation and
apoptosis in the mouse heart, and overexpression exacer-
bates ventricular remodeling after AMI (96), whereas spe-
ciﬁc CRP removal by apheresis reduced infarct size in
reperfused AMI in pigs (97). There have been no clinical
studies aimed at inhibiting or removing CRP in patients
with AMI to date.
Tumor necrosis factor (TNF)-a is a proinﬂammatory
cytokine released by inﬂammatory cells early in AMI
(98,99). TNF-a binds 2 types of receptors: TNF receptor 1
(TNFR1) and TNF receptor 2 (TNFR2). TNFR1 recruits
TNFR1-associated death domain protein leading to car-
diomyocyte death, whereas TNFR2 preferentially activates
cell survival pathways (100). TNF-a is up-regulated early in
AMI, promoting cardiac dysfunction (101), inﬂammation
(6), and cardiomyocyte apoptosis (102). Blockade of the
TNF-a system in experimental AMI, however, led to con-
ﬂicting results (103–105): TNFR1 mediates detrimental
effects of TNF-a after AMI, whereas data on the role of
TNFR2 in AMI are controversial (106,107). A small recent
clinical trial with etanercept, a TNF-a blocker acting as a
circulating trap, in 26 patients with AMI showed reduced
neutrophil count and plasma IL-6 concentrations at 24 h but
unexpectedly increased platelet-monocyte aggregation (108).
No other clinical trials to date have tested the effects of
TNF-a blockade in STEMI. However, disappointing re-
sults observed with TNF-a blockers (etanercept andetalloproteinases
t
Primary Endpoint
(Follow-Up) Results
tor)
Ventricular remodeling as
DLVESVI on echocardiography
(3 months)
Placebo: þ5.5 ml/m2 vs.
PG-116800: þ5.1 ml/m2
(p ¼ 0.42)
ice
days
Ventricular remodeling as
DLVESVI on echocardiography
(6 months)
Placebo: þ13.4% vs.
doxycycline þ0.4%
(p ¼ 0.012)
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1600inﬂiximab) in patients with HF, with a dose-dependent
increase in adverse cardiac events, signiﬁcantly lowered the
interest in these drugs for heart disease (109,110), and
TNF-a–blocking drugs are considered contraindicated in
patients with or at risk of HF. Clinical studies targeting
cytokines are summarized in Table 3.
Metalloproteinases. Metalloproteinases (MMPs) degrade
collagen and can contribute to scar thinning and aneurysm
formation and rupture in the infarcted area and to ven-
tricular dilation and remodeling in remote areas (Fig. 2).
Genetic blockade of MMP-2 (111) and MMP-9 (112)
were shown to reduce cardiac rupture and improve ven-
tricular remodeling after experimental AMI. PG-116800
is an oral MMP inhibitor with high afﬁnity for
MMP-2, -3, -8, -9, -13, and -14 and low afﬁnity for
MMP-1 and -7. In a phase II double-blind, multicenter
RCT PREMIER (Prevention of Myocardial Infarction
Early Remodeling) trial (113), PG-116800 given 2 days
after STEMI to 203 patients with primary PCI and left
ventricular ejection fraction 15% to 40% failed to improve
ventricular remodeling at 6 months. Doxycycline, a tetra-
cycline antibiotic, is also an MMP inhibitor that was
shown to prevent ventricular remodeling after experimental
AMI in rats through inhibition of MMP-2 and MMP-9
(114). In the phase II TIPTOP (Early Short-term
Doxycycline Therapy In Patients with Acute Myocardial
Infarction and Left Ventricular Dysfunction to Prevent
The Ominous Progression to Adverse Remodeling) trial
(115) (110 patients), treatment with doxycycline (100 mg
twice daily) starting immediately after PCI and continued
for 7 days was shown to reduce ventricular dilation at 6
months (increase in left ventricular end-systolic volume
index: 0.4% vs. 13.4%, p ¼ 0.012) and MACE (25.5% vs.
10.9%, p ¼ 0.04) in patients with STEMI and left ven-
tricular ejection fraction <40%. A phase II trial is
enrolling patients with HF and nonischemic cardiomy-
opathy (116). Clinical studies targeting MMPs are sum-
marized in Table 4.
Phosphoinositide 3-kinase. Phosphoinositide 3-kinase (PI3K)
is a broad family of enzymes that phosphorylate phospha-
tidylinositol, participating in cell growth, proliferation,
metabolism, migration, and inﬂammation in different cell
types (117). LY294002, a broad PI3K inhibitor, showed no
protective effect in ischemia-reperfusion (118). TG100-115,
in contrast, is a selective PI3Kg/PI3Kd inhibitor that was
shown to reduce infarct size after ischemia-reperfusion
in mice and pigs through reduction of inﬂammation and
edema (119). TG100-115 was tested in a phase I/II clinical
trial in patients with STEMI in 2005, although results have
not been published to date. Despite the proinﬂammatory
effects of PI3Kg in leukocytes, this isoform in car-
diomyocytes contributes to normal contractility (120), in-
dependent of the kinase activity (121), likely related to a
scaffold function modulating phosphodiesterase 3B. Genetic
deletion of PI3Kg led to adverse remodeling after AMI in
mice (122), whereas pharmacological inhibition withAS605240 (123) or genetic removal of the kinase activity
(122,124) showed improved or no effect on remodeling.
Immunoglobulin. Intravenous immunoglobulin (IVIG) is
a pooled human immunoglobulin G antibodies from donors,
with anti-inﬂammatory effects through several mechanism
(121). In rats with AMI, IVIG treatment reduced inﬂam-
matory cytokines and MMP-2, although it did not affect
survival or ventricular function at 7 days (125). A recent
phase II RCT in 62 STEMI patients randomized to IVIG
(0.4 mg/kg daily for 5 days, then monthly) or placebo
showed no effect in ventricular remodeling at 6 months by
cardiac magnetic resonance imaging (126).
Conclusions
Inﬂammation plays an important role in ventricular
remodeling after AMI. Modulation of the inﬂammatory
response represents a potential target for intervention.
Despite early encouraging results in pre-clinical models with
anti-inﬂammatory treatments, no beneﬁcial effects on top of
current medical treatments have been established in clinical
studies. The number of strategies reported to be useful in the
pre-clinical arena that have failed to show a beneﬁt in clinical
trials is disappointingly high due to many different and
potentially overlapping reasons: 1) the use of rodents, which
are signiﬁcantly different from humans; 2) use of healthy and
young animals that tend to exhibit an intense inﬂammatory
response; 3) experimental AMI is performed via surgical
ligation of a normal coronary artery, which differs substan-
tially from the process of atherothrombosis; and 4) new
therapies generally not tested in addition to current medical
treatment.
The initial studies in patients with STEMI used broad
inhibitors of inﬂammation that make it difﬁcult to inter-
pret results due to potential overlap of beneﬁcial and
deleterious effects. More recent studies in STEMI have
aimed at single targets or signaling pathways and have
provided some encouraging results that require validation.
This parallels the approach of single cytokine or receptor
targeting used in rheumatological and autoimmune dis-
ease. To date, no inﬂammatory inhibitor has been shown
to conclusively improve outcomes beyond that with stan-
dard treatment.
From an evolutionary standpoint, the inﬂammatory/im-
mune system appears to be a powerful adaptation to protect
our species from the ubiquitous microbial ﬂora, yet it is
deleterious against noninfectious diseases, leading to both a
chronic inﬂammatory response (as seen in atherosclerosis,
diabetes, and obesity) and an exaggerated acute inﬂamma-
tory response to tissue injury (as in AMI and stroke),
mediating further injury. Indeed, there is solid evidence that
inﬂammation plays a central pathological role in the pro-
gression of coronary atherosclerotic disease, AMI, and HF
(127). However, more studies are needed to determine the
most appropriate strategies to restore the inﬂammatory
balance and ameliorate remodeling after AMI.
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